Shrinivas Bishu

3.7k total citations · 1 hit paper
74 papers, 2.2k citations indexed

About

Shrinivas Bishu is a scholar working on Genetics, Surgery and Immunology. According to data from OpenAlex, Shrinivas Bishu has authored 74 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Genetics, 22 papers in Surgery and 22 papers in Immunology. Recurrent topics in Shrinivas Bishu's work include Inflammatory Bowel Disease (25 papers), Microscopic Colitis (13 papers) and Immunodeficiency and Autoimmune Disorders (12 papers). Shrinivas Bishu is often cited by papers focused on Inflammatory Bowel Disease (25 papers), Microscopic Colitis (13 papers) and Immunodeficiency and Autoimmune Disorders (12 papers). Shrinivas Bishu collaborates with scholars based in United States, France and Taiwan. Shrinivas Bishu's co-authors include Ryan W. Stidham, Sarah L. Gaffen, Akbar K. Waljee, Peter Higgins, Anna R. Huppler, Michael Rice, Nobuhiko Kamada, Hiroko Nagao‐Kitamoto, Sho Kitamoto and Kathryn A. Eaton and has published in prestigious journals such as Cell, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Shrinivas Bishu

69 papers receiving 2.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis

2020 459 citations Sho Kitamoto, Hiroko Nagao‐Kitamoto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shrinivas Bishu United States	26	628	574	545	505	427	74	2.2k
Emmilia Hodak Israel	40	287 0.5×	1.0k 1.8×	1.6k 2.9×	480 1.0×	766 1.8×	219	4.9k
William Ruff United States	16	313 0.5×	869 1.5×	307 0.6×	1.1k 2.2×	397 0.9×	22	2.3k
Shahla Abdollahi‐Roodsaz Netherlands	30	250 0.4×	1.9k 3.2×	385 0.7×	1.4k 2.8×	325 0.8×	50	3.6k
Emmanuella Guenova Switzerland	28	192 0.3×	1.3k 2.2×	984 1.8×	653 1.3×	569 1.3×	181	3.4k
Maxwell A. Fung United States	23	121 0.2×	637 1.1×	692 1.3×	351 0.7×	273 0.6×	125	2.3k
Jan Heidemann Germany	29	415 0.7×	763 1.3×	448 0.8×	751 1.5×	410 1.0×	65	2.5k
Steven K. Lundy United States	33	177 0.3×	1.8k 3.2×	323 0.6×	786 1.6×	505 1.2×	59	3.5k
Xavier Culleré United States	25	320 0.5×	1.8k 3.1×	367 0.7×	1.3k 2.5×	322 0.8×	38	3.9k
Haluk Barbaros Oral Türkiye	27	350 0.6×	496 0.9×	424 0.8×	673 1.3×	276 0.6×	96	2.1k
Martin W. Laaß Germany	24	776 1.2×	467 0.8×	669 1.2×	409 0.8×	66 0.2×	72	2.2k

Countries citing papers authored by Shrinivas Bishu

Since Specialization

Citations

This map shows the geographic impact of Shrinivas Bishu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shrinivas Bishu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shrinivas Bishu more than expected).

Fields of papers citing papers by Shrinivas Bishu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shrinivas Bishu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shrinivas Bishu. The network helps show where Shrinivas Bishu may publish in the future.

Co-authorship network of co-authors of Shrinivas Bishu

This figure shows the co-authorship network connecting the top 25 collaborators of Shrinivas Bishu. A scholar is included among the top collaborators of Shrinivas Bishu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shrinivas Bishu. Shrinivas Bishu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khan, Abdul Wali, Anthony Xu, Hyder Said, et al.. (2025). A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn’s disease. Journal of Crohn s and Colitis. 19(5). 2 indexed citations

Golob, Jonathan L., Guoqing Hou, Benjamin Swanson, et al.. (2024). Inflammation-Induced Th17 Cells Synergize with the Inflammation-Trained Microbiota to Mediate Host Resiliency Against Intestinal Injury. Inflammatory Bowel Diseases. 31(4). 1082–1094. 1 indexed citations

Golob, Jonathan L., Krishna Rao, Jeffrey Berinstein, et al.. (2024). Why Symptoms Linger in Quiescent Crohn’s Disease: Investigating the Impact of Sulfidogenic Microbes and Sulfur Metabolic Pathways. Inflammatory Bowel Diseases. 31(3). 763–776. 1 indexed citations

Huang, Katherine, Joel Pekow, Anish Patel, et al.. (2024). Tu1882 REAL-WORLD EFFECTIVENESS AND SAFETY OF UPADACITINIB IN CROHN'S DISEASE: A MULTICENTER STUDY. Gastroenterology. 166(5). S–1452.

Lee, Peter, Shrinivas Bishu, Amitabh Chak, et al.. (2024). SMART Medical Review: Acute Pancreatitis Assessment and Management in the First 24 Hours. 1(2). e19–e48.

Golob, Jonathan L., Krishna Rao, Jeffrey Berinstein, et al.. (2023). The Microbiome in Quiescent Crohn’s Disease With Persistent Symptoms Show Disruptions in Microbial Sulfur and Tryptophan Pathways. SHILAP Revista de lepidopterología. 3(2). 167–177. 2 indexed citations

Ham, Rebecca, et al.. (2023). USE OF UPADACITINIB IN 11 TOFACITINIB-REFRACTORY ULCERATIVE COLITIS PATIENTS AT A SINGLE TERTIARY CARE CENTER. Gastroenterology. 164(4). S103–S104. 1 indexed citations

Ham, Rebecca, et al.. (2023). USE OF UPADACITINIB IN 11 TOFACITINIB-REFRACTORY ULCERATIVE COLITIS PATIENTS AT A SINGLE TERTIARY CARE CENTER. Inflammatory Bowel Diseases. 29(Supplement_1). S81–S81. 4 indexed citations

Cheng, Shuyang, Michael Rice, Shrinivas Bishu, et al.. (2023). Mo1736 PREDICTING REMISSION EARLY IN ULCERATIVE COLITIS CLINICAL TRIALS USING COMPUTER VISION ANALYSIS OF ENDOSCOPIC VIDEO. Gastroenterology. 164(6). S–885. 1 indexed citations

10.

Stidham, Ryan W., Shuyang Cheng, Michael Rice, et al.. (2023). Using Computer Vision to Improve Endoscopic Disease Quantification in Therapeutic Clinical Trials of Ulcerative Colitis. Gastroenterology. 166(1). 155–167.e2. 30 indexed citations

11.

Grasberger, Helmut, Andrew T. Magis, Matthew P. Conomos, et al.. (2021). DUOX2 variants associate with preclinical disturbances in microbiota-immune homeostasis and increased inflammatory bowel disease risk. Journal of Clinical Investigation. 131(9). 42 indexed citations

12.

Berinstein, Jeffrey, Calen A. Steiner, Randolph E. Regal, et al.. (2018). Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 17(5). 988–990.e1. 68 indexed citations

13.

Bishu, Shrinivas, et al.. (2018). Perforated Meckel's Diverticulitis Mimicking Penetrating Crohn's Disease. Clinical Gastroenterology and Hepatology. 17(9). e105–e105. 1 indexed citations

14.

Tan, Bei, Jyh‐Chin Yang, Carol Young, et al.. (2017). Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience. Digestive Diseases and Sciences. 63(2). 437–445. 20 indexed citations

15.

El‐Zaatari, Mohamad, Adam J. Bass, Reanne Bowlby, et al.. (2017). Indoleamine 2,3-Dioxygenase 1, Increased in Human Gastric Pre-Neoplasia, Promotes Inflammation and Metaplasia in Mice and Is Associated With Type II Hypersensitivity/Autoimmunity. Gastroenterology. 154(1). 140–153.e17. 29 indexed citations

16.

Bishu, Shrinivas, Efstratios Koutroumpakis, Rawad Mounzer, et al.. (2017). The −251 A/T Polymorphism in the IL8 Promoter is a Risk Factor for Acute Pancreatitis. Pancreas. 47(1). 87–91. 8 indexed citations

17.

Conti, Heather R., Alanna Peterson, Lucas Brane, et al.. (2014). Oral-resident natural Th17 cells and γδ T cells control opportunistic Candida albicans infections. The Journal of Experimental Medicine. 211(10). 2075–2084. 202 indexed citations

18.

Qin, Mei, Kathleen Schmidt, Alan J. Zametkin, et al.. (2013). Altered Cerebral Protein Synthesis in Fragile X Syndrome: Studies in Human Subjects and Knockout Mice. Journal of Cerebral Blood Flow & Metabolism. 33(4). 499–507. 37 indexed citations

19.

Bishu, Shrinivas, Shrinivas Bishu, Joanna Quigley, et al.. (2007). Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leukemia & lymphoma. 48(8). 1548–1555. 42 indexed citations

20.

Bishu, Shrinivas, Shrinivas Bishu, Joanna Quigley, et al.. (2007). F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leukemia & lymphoma. 48(8). 1531–1538. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact